医学
贝伐单抗
内科学
胃肠病学
环磷酰胺
紫杉烷
进行性疾病
无进展生存期
卵巢癌
外科
实体瘤疗效评价标准
吉西他滨
拓扑替康
肿瘤科
化疗
癌症
乳腺癌
作者
Alfonso Sánchez-Muñoz,C. Mendiola,Carlos Aníbal Rodríguez,Elisabeth Pérez‐Ruiz,José Miguel Jurado,Lorenzo Alonso-Carrión,Ismael Ghanem,G. Deelasco,Cristina Quero Blanco,E Alba
标识
DOI:10.1200/jco.2010.28.15_suppl.e15507
摘要
e15507 Background: To assess the efficacy and safety of bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Methods: Patients with recurrent ovarian cancer and prior treatment with a platinum and taxane based chemotherapy were included. Treatment consisted of bevacizumab 10 mg/kg intravenously every two weeks plus oral cyclophosphamide 50 mg daily until disease progression or unacceptable toxicity. Response rates were determined according RECIST criteria and by monitoring the CA125 serum tumor marker according to Rustin' criteria. The endpoints were progression free disease (PFS), response rate (RR), overall survival (OS) and safety. Results: Thirty eight patients were treated, 79% were platinum resistant and 21% platinum sensitive. 79% of patients had received more than two previous lines of treatment. 81% of patients had received gemcitabine, 76% liposomal doxorubicin and 50 % topotecan. A median of 8 (r: 1-70) cycles of bevacizumab were administered. The overall response rate was a complete response (CR) in 3 patients (8.1%), a partial response (PR) in 12 (32.4%) and a stable disease ≥ 6 months (SD) in 3 (8.1%). Median PFS and overall survival were 4.5 and 10.7 months, respectively. 16 patients (42%) were progression free for at least 6 months. There was a significant relation of prior platinum response and performance status with the hazard of progression. Grade 3-4 toxicities included anemia (1), hypertension (2), hematuria (1), arterial thrombosis in the leg (1), dysnea (1) and intestinal fistulae (1). There were no cases of gastrointestinal perforation. Conclusions: The combination of bevacizumab and metronomic cyclophospamide was active and well tolerated for heavily pretreated recurrent ovarian cancer patients. No significant financial relationships to disclose.
科研通智能强力驱动
Strongly Powered by AbleSci AI